30 closest matches · ranked by relevance
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1 — 9.148; 18.18; 25.23; 38.32…
Healthy
Primary: Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C — 10920; 10720; 11200…
Multiple Sclerosis · Colitis, Ulcerative
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3; 2; 6 Participants
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in PART-1: SAD — 2; 1; 1; 0 Participants
Epilepsy
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 40.0; 0; 16.7; 83.3 percentage of participants
Autistic Disorder · Autism Spectrum Disorder · Child Development Disorders, Pervasive
Primary: Parts 1, 2 and 3: Percentage of Participants With Adverse Events — 2; 2; 2; 4 Participants
Healthy Volunteer
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-536 (the Active Moiety Derived From TAK-491) on Day 1 — 2877; 6250; 2444; 5460 nanogram per milliliter (ng/mL)
Healthy Participants
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 6 Participants
Healthy
Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants
Pharmacokinetic
Primary: Tmax (PEG 3350, Baseline-corrected Glycolic Acid and Baseline-corrected Ascorbic Acid) — 3.00; 9.00; 5.00 hours
Type 2 Diabetes Mellitus
Primary: Saxagliptin Maximum Observed Concentrations (Cmax) — 26.2; 25.5 ng/mL — p=0.4950
Pharmacokinetics and Pharmacodynamics
Primary: Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter — 55.28; 114.08; 246.00; NA ng/mL
Inflammatory Bowel Disease
Primary: Maximum Observed Concentration (Cmax) of PF-06480605 — 41530 nanogram per milliliter (ng/mL)
Schizophrenia
Primary: Lurasidone Cmax — 50.2 ng/mL
Healthy Participants
Primary: Total Recovery (Urine + Feces) of the Administered Radioactivity — 83.2 percentage of radioactivity
Wilson Disease
Primary: Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) Of Plasma Total Molybdenum After Each Dose…
Healthy
Primary: Safety and Tolerability of N91115 — 9; 6; 6; 6 participants
Healthy Volunteers · Brain Lesion
Primary: Pharmacokinetic (PK) Parameter Cmax — 248.7; 524.5; 698.7; 992.0 µg/mL
Healthy
Primary: The Mean (SD) Amount of [14C] Recovered in Urine, as a Percent of the Total [14C] Dose Administered — 25.2 percentage of dose
Healthy
Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 1780; 3680 Nanomol*Hour/Liter
Acute Coronary Syndrome
Primary: Adverse Events of LC23-1306
Healthy Volunteers
Primary: Maximal Plasma Concentration (Cmax) of AGN-223575 — 0.186; 0.128; 0.114; NA Nanograms/Milliliters (ng/mL)
Opioid-use Disorder
Primary: Median Cmax of Naltrexone (After 1st Dose) — 14.10 ng/mL
Healthy
Primary: Total Recovery of Radioactivity in Urine, Expressed as Percentage of Total Radioactive Dose Administered — 13.98 Percentage of total radioactive dose
Healthy
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event (TEAE) — 69.2; 83.3; 100.0; 66.7 percentage of participants
Healthy
Primary: Pharmacokinetics - Cmax (ng/mL) — 394.7; 322.8 ng/mL
Healthy Volunteers
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 50.0; 50.0; 33.3; 66.7 percentage of participants
Pharmacokinetics
Primary: Part 1: Maximum Observed Plasma Concentration (Cmax) of Apremilast — 205; 273; 373 ng/mL
Hepatic Impairment · Healthy Participants
Primary: Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours (AUC24) for PF-06651600 — 454.5; 383.6 nanogram*hour per milliliter (ng*hr/mL)